Related Experiment Video
Updated: Sep 25, 2025
In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant
Warren Rose1, Cecilia Volk1, Thomas J Dilworth2
1School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Abstract:
Vancomycin was introduced nearly 65 years ago and remains the standard antibiotic for serious methicillin-resistant Staphylococcus aureus (MRSA) infections. Staphylococcus aureus remains highly susceptibility to vancomycin (>97%). Despite this, MRSA treatment failure with vancomycin is high in complicated bacteremia. Additionally, vancomycin can cause nephrotoxicity, leading to new therapeutic drug monitoring guidance. This demonstrates how difficult it is to dose vancomycin in a way that is both efficacious and safe, especially during long courses of therapy. Often underappreciated are the cost, resources, and complexity of vancomycin care at a time when alternative antibiotics are becoming cost comparable. This perspective highlights a bigger picture of how the treatment repertoires of many other diseases have changed and advanced since vancomycin's introduction in the 1950s, yet the vancomycin MRSA treatment standard remains. While vancomycin can still have a role, 65 years may be a practical retirement age for vancomycin in highly complex endovascular infections.
Insights
Vancomycin, an antibiotic used for decades against MRSA, has high treatment failure rates and risks of harm. Newer, cost-comparable alternatives may be better for complex infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Antimicrobial Resistance
Background:
- Vancomycin has been the standard treatment for serious methicillin-resistant Staphylococcus aureus (MRSA) infections for nearly 65 years.
- Despite high susceptibility rates (>97%), vancomycin treatment failure is common in complicated MRSA bacteremia.
- Vancomycin use is associated with nephrotoxicity, necessitating therapeutic drug monitoring and complicating long-term therapy.
Purpose of the Study:
- To evaluate the continued appropriateness of vancomycin as the primary antibiotic for MRSA infections.
- To highlight the challenges in optimizing vancomycin dosing for efficacy and safety.
- To consider the cost, resource implications, and complexity of vancomycin care in the context of evolving treatment options.
Main Methods:
- This is a perspective piece, not a primary research study.
- It involves a critical review of current vancomycin use against MRSA.
- It compares historical treatment standards with contemporary medical advancements and alternative therapies.
Main Results:
- Vancomycin exhibits high failure rates in complicated MRSA bacteremia despite preserved susceptibility.
- Dosing vancomycin for both safety and efficacy, especially in long-term therapy, remains challenging.
- The cost and complexity of vancomycin care are increasingly comparable to newer antibiotics.
Conclusions:
- Sixty-five years after its introduction, vancomycin may no longer be the optimal choice for MRSA treatment, particularly in complex endovascular infections.
- Alternative antibiotics, which have advanced significantly since vancomycin's introduction, should be considered.
- A re-evaluation of vancomycin's role in the MRSA treatment paradigm is warranted.
Related Concept Videos
01:18Endocarditis III: Medical Management
01:29Endocarditis IV: Nursing Management
01:28Antimicrobial Effectiveness